



**BioLight Life Sciences Ltd.
(The "Company")**

20 February 2023

**To:
Israel Security Authority**

www.isa.goc.il

**TASE- Tel Aviv Stock Exchange
www.tase.co.il**

**Re: OPHRX Ltd. (Subsidiary)
Recruitment of the First Participants in a Clinical Trial**

The Company is honored to announce that on February 19, 2023, OphrX, Ltd. ("OphrX") a subsidiary of the Company has informed it that it has recruited the first 2 participants in a human clinical trial based on its technological eye drops containing the active ingredient Cyclosporine whose concentration is two times higher than the products currently on the market possessing comparatively lower concentrations (the "Trial").

To the best of the Company's knowledge, as informed by OphrX, the main purpose of the trial, which is conducted at Jerusalem's Shaare Zedek Hospital, intends to include about 20 healthy participants, comparing the tolerance, safety and ease of use its higher concentrated to the ones currently on the market, which has an annual turnover of about one billion US dollars in the United States.

To the best of the Company's knowledge, as informed by OphrX, the cyclosporine-based eye drops currently sold on the market (in concentrations ranging from 0.05% to 0.09%) are currently used to treat patients with dry eye. According to reports, these products may cause discomfort such as burning of the eye while taking several months before they begin to take effect.

OphrX will try to demonstrate through its trial that there is no significant difference of discomfort for the users of its product in comparison to the low dose on the current market. OphrX regards the higher concentration as a potential to shorten the time relief is attained and improved for dry eye patients in addition to the possibility that the product may be suitable for patients with severe dry eye symptoms as well as for additional front of the eye diseases.

According to OphrX' assessment, in accordance with and subject to the rate of recruitment of participants, the trial is expected to end by the third quarter of 2023.



About OphrX

OphrX a subsidiary company of the Company, is engaged in the development of drugs for the treatment of eye diseases through an innovative technological platform that enhances the transmission of ocular substances based on nanostructures.

About BioLight

BioLight Life Sciences Ltd. is a leading company investing in companies and managing projects in the field of eye diseases and ocular treatments. BioLight's portfolio companies engage in advanced medical devices, medication, diagnostics and digital medicine designed to improve the efficacy and safety of treatments of eye diseases exemplifying the enormous potential of Israeli innovation in these fields.